Skip to Main Content

A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Conditions

Prostate | Diseases of the Kidney & Urinary Tract | Men's Health

Phase I-II

What is the purpose of this trial?

Assessment of the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68Ga-PSMA-R2, to assess the pharmacokinetics (PK), biodistribution, and dosimetry of 68Ga-PSMA-R2, and to establish the optimal imaging method for determining location and burden of positive lesions in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).

  • Ages
    18 years and older
  • Gender
    Male only
  • Trial with
    Advanced Accelerator Applications International SA
  • Start Date
    03/03/2019
  • End Date
    11/18/2019
Trial Image

For more information about this study, contact:

Svetlana Vassilieva

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/22/2019
  • Study HIC
    #2000023359